Oncology Trial Reveals Promising Preliminary Phase 1 Results
In an ongoing Phase 1 trial of 12 patients with metastatic BRCA/PALB2-associated cancers (11 pancreatic ductal adenocarcinoma and one...
IO Biotech Unveils Phase 3 Cylembio Melanoma Trial Results
Cylembio plus pembrolizumab delivered a median progression-free survival of 19.4 months versus 11.0 months with pembrolizumab alone in previously...
RAPT to Report Topline Phase 2 Data for RPT904 in CSU
RAPT Therapeutics will release topline results on Monday from a partner-run Phase 2 trial of RPT904 in chronic spontaneous...
ESMO 2025: Promising RP1/Nivolumab Acral Melanoma Data
RP1 plus nivolumab produced a 44% objective response rate (8/18) in an ad hoc analysis of acral melanoma patients...
Risk-Based Oversight Redefined: How E6R3 is Reshaping Vendor Governance
At the SCOPE Europe 2025 conference, industry experts underscored how ICH E6(R3) is transforming the way sponsors approach vendor...
Imaging as Infrastructure: Why Sponsors Must Rethink Oversight in Modern Trials
At DPHARM, we spoke with Paul McCracken, founder and principal of RadiaNova Consulting, about the overlooked pitfalls in clinical...
CRB-701: Remarkable Clinical Responses in HNSCC Cancers
At the 3.6 mg/kg dose of CRB-701, Corbus reported objective response rates of 47.6% in head and neck squamous...
Olema Announces New Data from Palazestrant Cancer Trial
Median PFS reached 15.5 months in the 120 mg palazestrant cohort across all comers, with 12.2 months among patients...
Disc Medicine Presents New Phase 1b CKD/Anemia Trial Data
Disc Medicine will deliver a full Phase 1b update of DISC-0974 in non-dialysis-dependent chronic kidney disease (NDD-CKD) patients with...
AI Cancer Vaccine Shows Surging 75% Response in Phase 2 Trial
Evaxion reported a 75% objective response rate in a 16-patient Phase 2 study of EVX-01 plus pembrolizumab in first-line...